Sensus Blog

The future of skin cancer treatment is now. Stay ahead of the curve with our library of informational blogs.

April
27
2026

Basal Cell Carcinoma vs. Squamous Cell Carcinoma: What’s the Difference?

Melanoma and non-melanoma are two primary categories of skin cancer. Each presents different symptoms and treatment options. Within the non-melanoma skin cancer – sometimes referred to as NMSC – category, the two most common types…

February
19
2024

The Benefits of Superficial Radiotherapy (SRT)

Non-melanoma skin cancer is one of the most common types of skin cancer, with millions of new cases reported each year. While there are various treatment options available, one of the most effective and widely…

February
08
2024

Sensus Healthcare Reports Fourth Quarter and Full Year 2023 Financial Results

Fourth quarter revenues of $12.6 million up three-fold sequentially, reflect ongoing customer adjustment to macroeconomic conditions Introduces recurring revenue model for the SRT-100 Vision™ (IG-SRT) to address dermatologist demand Conference call begins at 4:30 p.m….

February
08
2024

Sensus Healthcare Issued U.S. Patent for SRT-100 Vision® System (IG-SRT) Capabilities

BOCA RATON, Fla., Feb. 08, 2024 — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that the U.S. Patent…

February
06
2024

Sensus Healthcare Collaborates with CureRays to Provide Oversight to Help Customers Assure Patient Safety, Reliability of Outcomes and Conformance with Regulatory Requirements

Physician-run radiation oncology innovator also to research new indications and broaden the market for SRT to include inflammatory diseases BOCA RATON, Fla., Feb. 06, 2024 — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company…

Archives
Archives

IN THE NEWS

CEO Joseph Sardano on Coding for Superficial Radiation Therapy